Please ensure Javascript is enabled for purposes of website accessibility

Why Akebia Therapeutics Stock Is Crashing Today

By Keith Speights – Sep 3, 2020 at 11:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's lead pipeline candidate fell short in a late-stage clinical study.

What happened

Shares of Akebia Therapeutics (AKBA -1.20%) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a late-stage study of vadadustat in treating anemia due to chronic kidney disease (CKD) in adult patients not on dialysis. While the experimental drug met the primary and secondary efficacy endpoints of the study, it didn't meet the primary safety endpoint.

So what

It's not surprising that investors bailed on the biotech stock after the late-stage results were announced. A drug isn't likely to be approved by the FDA if there are concerns that it isn't safe.

Man looking at red line plunging through the floor

Image source: Getty Images.

However, Akebia said that it still plans to file for FDA approval of vadadustat. Why? CEO John Butler stated, "We believe the cardiovascular safety of vadadustat is supported by the totality of the data from our global Phase 3 program."

Vadadustat has been evaluated in two late-stage studies. The results from an earlier phase 3 trial of the drug in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis were overwhelmingly positive. Akebia thinks that it has a shot at winning FDA approval for vadadustat in both dialysis and non-dialysis settings based on the combined data from both studies.

Now what

Akebia and its partner, Japanese drugmaker Otsuka, plan to meet with the FDA before the end of 2020. The companies intend to submit for U.S. regulatory approval of vadadustat in the dialysis and non-dialysis indications "as early as possible next year."

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Akebia Therapeutics, Inc. Stock Quote
Akebia Therapeutics, Inc.
AKBA
$0.30 (-1.20%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.